Prils Market | Leading Segments, Trends, Drivers and Challenges
Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. are some of the leading market vendors
The prils market is expected to grow by $ 784.14 million, accelerating at a CAGR of almost 5.43% during the forecast period. Technavio’s research reports offer a detailed analysis of the market segments, delving deep into the factors that will lead to the growth of each segment. It also offers insights into factors that are likely to have a negative impact on market growth. This comprehensive analysis of the market will enable clients to identify areas of growth and steer clear of the low-performing segments.
Request for Our Free Sample Report for detailed Insights
Prils Market: Market Segments and Growth Forecasts
This research report will provide insights into the current market share of each segment along with growth projections for the next five years.
- Market is segmented by Application (Hypertension, Heart failure, and Chronic kidney disorders) and Geography (North America, Europe, Asia, and ROW).
- Market growth by the hypertension segment will offer significant growth during the forecast period.
- 40% of the market growth will originate from North America during the forecast period. The US and Canada are the key markets for prils in North America. However, market growth in this region will be slower than the growth of the market in Asia and Europe. The significant increase in the geriatric population and high demand for CVD drugs for the treatment of cardiovascular diseases (CVDs) will facilitate the prils market growth
This report provides an accurate prediction of the contribution of all the geographic segments to the growth of the Prils Market size.
Prils Market: Trends, Drivers, Challenges
The report also offers a detailed impact analysis of various trends, drivers, and challenges that are likely to influence the market growth during the forecast period. These insights will equip clients to design a growth strategy for their business and area of operations.
- Rising geriatric population will be a significant factor in driving the growth of the Prils Market. The increase in the aging population is a matter of concern for many countries such as China, US, and Japan. This growing population requires medical services, which in turn will positively impact the market in focus during the forecast period.
- The high incidence of cardiovascular diseases (CVDs) has led governments to increase investment in R&D of hypertension and cardiovascular medicines which will drive the global prils market growth.
- Certain chronic diseases such as obesity, diabetes, and high cholesterol increase the risk of heart disease, thereby increasing the demand for CVD drugs which in turn will further stimulate growth in the prils market.
- Side effects of prils is a serious hurdle to market growth as the drugs used for the treatment of heart failure and hypertension have many side effects such as dizziness, ringing or buzzing in the ears, diarrhea, high potassium levels in the blood. However, the role of medicines is to mitigate the more serious ailment hence, in several cases the long term benefits of these medicines will override the side-effects.
Prils Market: Vendor Analysis
- The market is fragmented.
- Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Fazio Group of Companies, Lupin Ltd., Manus Aktteva Biopharma LLP, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc. are some of the major market participants.
- The unprecedented outbreak of COVID-19 in 2020 has had a significant impact on market segments had a ripple effect on various stakeholders. Our vendor analysis and insights will provide you with all the information required to make the most of the opportunities and plan business recovery and growth post the pandemic.
Key Areas Covered in our Report:
- Prils Market Split by Application
- Hypertension
- Heart failure
- Chronic kidney disorders
- Prils Market Split by Geography
- North America
- Europe
- Asia
- ROW
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- APAC - Market size and forecast 2020-2025
- MEA - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- North America - Market size and forecast 2020-2025
- South America - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Aurobindo Pharma Ltd.
- Dr. Reddys Laboratories Ltd.
- Fazio Group of Companies
- Lupin Ltd.
- Manus Aktteva Biopharma LLP
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
For more insights into this market: Download a Free Sample Report. Our custom reports provide market insights at the global and regional level along with pipeline analysis of new product launches. It also provides a peek into the latest R&D along with an impact analysis of government regulations.
The report provides insights into the following FAQs:
- What is the market CAGR?
The market will accelerate at a CAGR of 5.43%.
- What is the incremental growth of the market?
The market is expected to grow by $ 784.14 mn through 2022-2026.
- What is a key factor driving this market?
Rising geriatric population will drive market growth over the forecast period.
- What are the key regions covered in this market research report?
North America, Europe, Asia, and ROW are the key regions featured in this research report.
- Which is the leading geographic region for this market:
40% growth will originate from North America
- Who are the leading market vendors?
The leading vendors in this market are Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Fazio Group of Companies, Lupin Ltd., Manus Aktteva Biopharma LLP, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc.
- What are the market segments covered in this report?
The market is segmented by Application (Hypertension, Heart failure, and Chronic kidney disorders) and Geography (North America, Europe, Asia, and ROW)
